AR086924A1 - Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion - Google Patents
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacionInfo
- Publication number
- AR086924A1 AR086924A1 ARP120102104A ARP120102104A AR086924A1 AR 086924 A1 AR086924 A1 AR 086924A1 AR P120102104 A ARP120102104 A AR P120102104A AR P120102104 A ARP120102104 A AR P120102104A AR 086924 A1 AR086924 A1 AR 086924A1
- Authority
- AR
- Argentina
- Prior art keywords
- epo receptor
- human
- antibody
- lpgpggsvdiv
- receptor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 abstract 13
- 108020003175 receptors Proteins 0.000 abstract 13
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract 7
- 102000044890 human EPO Human genes 0.000 abstract 7
- 108010092408 Eosinophil Peroxidase Proteins 0.000 abstract 6
- 102100031939 Erythropoietin Human genes 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 4
- 210000002889 endothelial cell Anatomy 0.000 abstract 3
- 238000000338 in vitro Methods 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Describe también un anticuerpo que se une de forma especifica al receptor de la EPO humano, en el que el anticuerpo se une al fragmento del receptor de la EPO LPGPGGSVDIV (Id. de Sec. Nº 01) pero no se une específicamente a una proteína que puede obtenerse a partir de células endoteliales humanas que posee un peso molecular de alrededor de 66 kD.Reivindicación 1: Un método para la detección in vitro del receptor de la EPO humano que comprende los siguientes pasos: determinar in vitro la presencia del receptor de la EPO humano en una muestra mediante la incubación de la muestra con un anticuerpo contra el receptor de la EPO que se une de forma específica al fragmento del receptor de la EPO humano LPGPGGSVDIV (Id. de Sec. Nº 01) y así se detecta in vitro el receptor de la EPO humano, en el que el anticuerpo del receptor de la EPO que se une de forma específica al fragmento del receptor de la EPO LPGPGGSVDIV (Id. de Sec. Nº 01) no se une específicamente a una proteína que puede obtenerse a partir de células endoteliales humanas y que posee un peso molecular de alrededor de 66 kD. Reivindicación 5: La utilización de un anticuerpo que se une de forma específica al receptor de la EPO humano, que se caracteriza porque el anticuerpo se une al fragmento del receptor de la EPO LPGPGGSVDIV (Id. de Sec. Nº 01) y no se une específicamente a una proteína que puede obtenerse a partir de células endoteliales humanas y que posee un peso molecular de alrededor de 66 kD, para detectar el receptor de la EPO humano. Reivindicación 13: Una formulación farmacéutica que comprende el anticuerpo de cualquiera de las reivindicaciones de 2 a 4 y un transportador aceptable a nivel farmacéutico. Reivindicación 14: Un ácido nucleico aislado que codifica el anticuerpo de acuerdo con cualquiera de las reivindicaciones de 2 a 4. Reivindicación 15: Una célula huésped que comprende el ácido nucleico de la reivindicación 14. Reivindicación 17: La utilización de un anticuerpo de acuerdo con cualquiera de las reivindicaciones de 2 a 4 para el análisis del receptor de la EPO en una muestra de tejido o célula humanos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11170020 | 2011-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086924A1 true AR086924A1 (es) | 2014-01-29 |
Family
ID=45044836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102104A AR086924A1 (es) | 2011-06-15 | 2012-06-14 | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8623666B2 (es) |
| EP (1) | EP2721067B1 (es) |
| JP (1) | JP5984919B2 (es) |
| KR (1) | KR101629073B1 (es) |
| CN (1) | CN103596984B (es) |
| AR (1) | AR086924A1 (es) |
| AU (1) | AU2012269075B2 (es) |
| BR (1) | BR112013032235A2 (es) |
| CA (1) | CA2837914A1 (es) |
| IL (1) | IL229764A0 (es) |
| MX (1) | MX343117B (es) |
| MY (1) | MY166974A (es) |
| RU (1) | RU2013158627A (es) |
| WO (1) | WO2012171996A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2928921B1 (en) | 2012-12-05 | 2021-01-20 | Novartis AG | Compositions and methods for antibodies targeting epo |
| KR101539150B1 (ko) * | 2013-12-26 | 2015-07-27 | 가톨릭대학교 산학협력단 | 자가면역 항체 검출방법 및 이를 이용한 자가면역 항체 검출키트 |
| JP6841609B2 (ja) | 2015-07-10 | 2021-03-10 | ３スキャン インコーポレイテッド | 組織学的染色の空間的多重化 |
| JP2018525389A (ja) | 2015-08-12 | 2018-09-06 | ノバルティス アーゲー | 眼障害を治療する方法 |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4966852A (en) | 1987-07-23 | 1990-10-30 | Monsanto Company | DNA clone of human tissue factor inhibitor |
| IL87171A (en) * | 1987-11-23 | 1995-08-31 | Monsanto Co | cDNA of human tissue factor inhibitor |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1514934B1 (en) | 1992-02-06 | 2008-12-31 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| CA2169629C (en) | 1993-08-16 | 2002-06-11 | Jong Y. Lee | Human erythropoietin receptor fragment and antibodies thereto |
| EP0702553A1 (en) | 1993-12-27 | 1996-03-27 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Water soluble non-immunogenic polyamide cross-linking agents |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU6163196A (en) | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP1169352A4 (en) | 1999-04-14 | 2005-05-04 | Smithkline Beecham Corp | ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR |
| US6998124B1 (en) | 1999-04-14 | 2006-02-14 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
| EP1074563A1 (en) | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| JP2003512821A (ja) | 1999-10-04 | 2003-04-08 | メディカゴ インコーポレイテッド | 外来性遺伝子の転写調節方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| EP2857516B1 (en) | 2000-04-11 | 2017-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| US20040058393A1 (en) | 2000-04-17 | 2004-03-25 | Naoshi Fukishima | Agonist antibodies |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| EP1327681A4 (en) | 2000-10-20 | 2004-09-01 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibodies |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
| MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| EP1500698B1 (en) | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| DE10344737B3 (de) | 2003-09-26 | 2004-08-26 | LAUKÖTTER, Karl-Heinz | Gegenkolbenmotor nach Art eines Zweitaktmotors |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
| KR101364902B1 (ko) | 2003-11-05 | 2014-02-21 | 로슈 글리카트 아게 | 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체 |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| WO2005080562A1 (ja) * | 2004-02-23 | 2005-09-01 | Hiroshi Yamamoto | 前立腺癌の判定方法 |
| ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| US20050227289A1 (en) | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| US20060018902A1 (en) | 2004-04-09 | 2006-01-26 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
| HRP20130440T1 (en) | 2004-04-13 | 2013-06-30 | F. Hoffmann - La Roche Ag | Anti-p-selectin antibodies |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2009053987A1 (en) | 2007-10-25 | 2009-04-30 | University Of Bristol | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
| US20090181037A1 (en) | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
| US8357501B2 (en) * | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
| WO2009068677A1 (en) * | 2007-11-29 | 2009-06-04 | Alepor Gmbh & Co. Kg | Novel tissue protective erythropoietin receptor (nepor) and methods of use |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| EP2321350A1 (en) | 2008-08-28 | 2011-05-18 | F. Hoffmann-La Roche AG | Antibodies against human epo receptor |
| EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| WO2010081679A2 (en) | 2009-01-15 | 2010-07-22 | F. Hoffmann-La Roche Ag | Antibodies against human epo receptor |
| EP2414391B1 (en) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
| TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
-
2012
- 2012-06-14 AR ARP120102104A patent/AR086924A1/es unknown
- 2012-06-14 MX MX2013013937A patent/MX343117B/es active IP Right Grant
- 2012-06-14 BR BR112013032235A patent/BR112013032235A2/pt not_active IP Right Cessation
- 2012-06-14 CA CA2837914A patent/CA2837914A1/en not_active Abandoned
- 2012-06-14 WO PCT/EP2012/061288 patent/WO2012171996A1/en not_active Ceased
- 2012-06-14 RU RU2013158627/10A patent/RU2013158627A/ru not_active Application Discontinuation
- 2012-06-14 CN CN201280029140.0A patent/CN103596984B/zh not_active Expired - Fee Related
- 2012-06-14 US US13/517,826 patent/US8623666B2/en active Active
- 2012-06-14 MY MYPI2013004527A patent/MY166974A/en unknown
- 2012-06-14 JP JP2014515188A patent/JP5984919B2/ja not_active Expired - Fee Related
- 2012-06-14 AU AU2012269075A patent/AU2012269075B2/en not_active Ceased
- 2012-06-14 KR KR1020137033166A patent/KR101629073B1/ko not_active Expired - Fee Related
- 2012-06-14 EP EP12728475.0A patent/EP2721067B1/en active Active
-
2013
- 2013-12-02 IL IL229764A patent/IL229764A0/en unknown
- 2013-12-05 US US14/097,972 patent/US9187563B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103596984B (zh) | 2016-04-13 |
| KR101629073B1 (ko) | 2016-06-09 |
| CN103596984A (zh) | 2014-02-19 |
| NZ617936A (en) | 2015-10-30 |
| US9187563B2 (en) | 2015-11-17 |
| MX343117B (es) | 2016-10-25 |
| US20120321633A1 (en) | 2012-12-20 |
| HK1193615A1 (zh) | 2014-09-26 |
| JP5984919B2 (ja) | 2016-09-06 |
| US8623666B2 (en) | 2014-01-07 |
| RU2013158627A (ru) | 2015-07-20 |
| IL229764A0 (en) | 2014-01-30 |
| EP2721067A1 (en) | 2014-04-23 |
| MY166974A (en) | 2018-07-27 |
| AU2012269075B2 (en) | 2015-05-21 |
| US20140193418A1 (en) | 2014-07-10 |
| EP2721067B1 (en) | 2019-07-31 |
| MX2013013937A (es) | 2013-12-16 |
| CA2837914A1 (en) | 2012-12-20 |
| AU2012269075A1 (en) | 2013-05-02 |
| WO2012171996A1 (en) | 2012-12-20 |
| KR20140013076A (ko) | 2014-02-04 |
| JP2014528693A (ja) | 2014-10-30 |
| BR112013032235A2 (pt) | 2016-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Riemekasten et al. | Involvement of functional autoantibodies against vascular receptors in systemic sclerosis | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| EA202090652A1 (ru) | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras | |
| WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
| BR112014008849A2 (pt) | receptores quiméricos de antígeno anti-cd22 | |
| BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| AR102732A1 (es) | Moléculas de unión a antígeno biespecíficas activadoras de células t | |
| CL2012000822A1 (es) | Acido nucleico aislado del virus de peces prv; polipeptido aislado; anticuerpo que se une a dicho polipeptido; metodo para determinar la presencia o ausencia de prv en una muestra biologica; arn interferente; metodo para reducir nivel de proteina viral. | |
| NI200900027A (es) | Anticuerpos monoclonales humanos específicos para light humanos antagonistas. | |
| AR070168A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos | |
| AR098126A1 (es) | Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos | |
| JP2015533788A5 (es) | ||
| MX2015003061A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. | |
| CL2012002700A1 (es) | Anticuerpo humanizado capaz de logarse especificamente a receptores de quimioquina 4 (cxcr4); molecula de acido nucleico aislada que codifica dicho anticuerpo; vector y célula que comprenden dicho acido nucleico; composicion que comprende dicho anticuerpo; proceso de deteccion in vitro de la presencia y/o la ubicacion de un tumor que expresa cxcr4. | |
| BRPI0812428A2 (pt) | vírus, ácido nucleico isolado ou recombinante ou fragmento específico de totv do mesmo, vetor de expressão, polinucleotídeo, polipeptídeo isolado ou recombinante, antígeno, anticorpo, métodos para produzir um anticorpo contra um vírus, para identificar um isolado viral como um vírus, para detectar a presença de um vírus em uma amostra, para identificar uma planta que seja resistente a um vírus, e para produzir uma planta que seja resistente a um vírus, e, usos de um vírus, ácido nucleico isolado ou recombinante ou fragmento específico de totv do mesmo, vetro de expressão, polinucleotídeo, polipeptídeo isolado ou vírus, para identificar um isolado viral com vírus, para detectar a presença de um vírus em uma amostra, para identificar uma planta que seja resistente a um vírus, e para produzir uma planta que seja resistente a um vírus, e, usos de um vírus, e de uma forma atenuada de um vírus | |
| MX2014011504A (es) | Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus. | |
| BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer | |
| EP2582849A4 (en) | DETECTION OF NUCLEIC ACIDS AND PROTEINS | |
| CY1115624T1 (el) | Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ | |
| RU2014120577A (ru) | Моноклональное антитело cd44 для лечения b-клеточной хронической лимфоцитарной лейкемии и других гематологических злокачественных заболеваний | |
| WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
| AR086924A1 (es) | Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion | |
| WO2011127001A3 (en) | Quantum dot-based optical sensors for rapid detection and quantitative analysis of biomolecules and biological materials | |
| UA108349C2 (uk) | Гуманізоване антитіло з протипухлинною активністю |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |